106.15
116.00
90.80
144.99
3.50
442.40
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
Current Price
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
We appreciate your patience. Your content is on the way.
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Mangalam Drugs and Organics Ltd is an India-based company. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates. The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra. They also have an in-house Research and Development (R&D) Base. Their products include chloroquine phosphate I.P., aluminum chloride anhydrous, and dyes and intermediaries. Mangalam Drugs and Organics Ltd was incorporated on April 18, 1972 as a private limited company with the name Advent Pharma Pvt Ltd. The company was promoted by Dhoot family. The company was established with a view to set up a plant for manufacture of organic and inorganic chemicals. In April 1, 1996 three other group companies, namely Mangalam Organics Pvt Ltd, Shree Mangalam Pharma Pvt Ltd and Mangalam Rasayan Pvt Ltd were amalgamated with the company. In July 1, 1997, the company changed their name from Advent Pharma Pvt Ltd to Mangalam Drugs and Organics Pvt Ltd. In September 22, 1997, the company was converted into a deemed public company and word `private` was deleted from the company`s name. In the year 1999, the company launched a new product namely, Nimesulide. In the year 2001, they launched two new products namely Amodiaquine Hydrochloride and Amodiaquine. In August 10, 2001, the company was converted into a full fledged public limited company. In the year 2003-2004, the bulk drug production capacity of the Company was increased from 350 MTPA to 600 MTPA. During the 2004-05, the capacity is being further enhanced to 960 MTPA. During the year 2005-06, the company further enhanced their Bulk drug production capacity from 960 MT per annum to 1260 MT per annum. During the year 2007-08, the company developed and introduced new bulk drugs namely Bisoprolol Fumarate and Pantaprazole Sodium. Also, they increased the production capacity of Meta Chloro Aniline & Allied Products from 250 tons to 350 tons. During the year 2009-10, the company in addition to Regulatory Affairs Cell established Intellectual Property Rights (IPR) cell. The regulatory affairs cell submitted 6 DMFs to WHO-Geneva out of which 2 DMFs corresponding to Artemether and Lumefantrine had been approved.
Mangalam Drugs and Organics share price as on 08 Feb 2025 is Rs. 113.12. Over the past 6 months, the Mangalam Drugs and Organics share price has increased by 0.64% and in the last one year, it has decreased by 3.15%. The 52-week low for Mangalam Drugs and Organics share price was Rs. 90.8 and 52-week high was Rs. 144.99.
532637
MANGALAM
INE584F01014
Sep
You can buy Mangalam Drugs and Organics Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Mangalam Drugs and Organics Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 07, 2025 03:44 PM the closing price of Mangalam Drugs and Organics Ltd was Rs.113.12.
The latest PE ratio of Mangalam Drugs and Organics Ltd as of Feb 07, 2025 03:44 PM is 19.19
The latest PB ratio of Mangalam Drugs and Organics Ltd as of Feb 07, 2025 03:44 PM is 0.83
The 52-week high of Mangalam Drugs and Organics Ltd share price is Rs. 144.99 while the 52-week low is Rs. 90.80
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Feb 07, 2025 03:44 PM, the market cap of Mangalam Drugs and Organics Ltd stood at Rs. 179.05 Cr.
We appreciate your patience. Your content is on the way.